Table 3.

Prevalence of high grade cancer in low risk patients with PSA between 10 and 25 ng/ml, by cohort. Cohorts were included if they were independent validations of the contemporary 4Kscore model.

Cohort	Low Risk Men	High Grade Cancer Among Low Risk Men
PSA 10 – 25 ng / mL (n=255)
<7.5% risk threshold
OPKO (N=102)	22 (22%)	1 (4.5%)
UPCA (N=153)	12 (8%)	0 (0.0%)
Total	34 (13%)	1 (2.9%)
<10% risk threshold
OPKO (N=102)	24 (24%)	1 (4.2%)
UPCA (N=153)	16 (10%)	0 (0.0%)
Total	40 (16%)	1 (2.5%)
Positive DRE (n=449)
<7.5% risk threshold
OPKO (N=240)	61 (25%)	0 (0.0%)
UPCA(N=209)	6 (3%)	1 (16.7%)
Total	67 (15%)	1 (1.5%)
<10% risk threshold
OPKO (N=240)	81 (34%)	1 (1.2%)
UPCA (N=209)	12 (6%)	1 (8.3%)
Total	93 (21%)	2 (2.2%)
PSA 10 – 25 ng / mL or positive DRE (n=615)
Total: <7.5% threshold
OPKO (N=321)	81 (25%)	1 (1.2%)
UPCA (N=294)	17 (6%)	1 (5.9%)
Total	98 (16%)	2 (2.0%)
Total: <10% threshold
OPKO (N=321)	103 (32%)	2 (1.9%)
UPCA (N=294)	26 (9%)	1 (3.8%)
Total	129 (21%)	3 (2.3%)